The U. S. Food and Drug Administration (FDA) on Monday lifted the clinical hold on GH Research Plc's (NASDAQ:GHRS) Investigational New Drug Application (IND) for GH001.

GAITHERSBURG, Md. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced the U.

(RTTNews) - ScinoPharm Taiwan (TWSE: 1789) today announced that the U. S. FDA has approved its Glatiramer Acetate Injection, a generic version of Teva's Copaxone, for the treatment of adult patients with multiple sclerosis.

Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1D in children aged one and older diagnosed with stage 2 T1DTzield slows disease progression by protecting the insulin-secreting beta cells of the pancreasThe priority review is based on interim results from the PETITE-T1D phase 4 study Paris, January 5, 2026.

All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here TAINAN , Jan.

CORT's strong balance sheet enables pursuit of additional clinical evidence to address the FDA's concerns and potentially secure Relacorilant approval.